CYP2B6 and metabolic dysfunction-associated steatotic liver disease: The proteomics analyses strongly indicated that bicyclol was an underlying therapeutic drug for NAFLD attenuating by modulating multiple pathways such as bile acid metabolism, immune response, inflammatory and oxydoredution reaction, and the P450 pathway.